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ABSTRACT
BACKGROUND: Stents are commonly used to treat patients with coronary artery disease. However, the
quality of reporting internal and external validity data in published reports of randomised controlled trials
(RCTs) of stents has never been assessed.
The objective of our study was to evaluate the quality of reporting internal and external validity data in
published reports of RCTs assessing the stents for percutaneous coronary interventions.
METHODS: A systematic literature review was conducted. Reports of RCTs assessing stents for
percutaneous coronary interventions indexed in MEDLINE and the Cochrane Central Register of
Controlled Trials and published between January 2003 and September 2008 were selected. A
standardized abstraction form was used to extract data. All analyses were adjusted for the effect of
clustering articles by journal.
RESULTS: 132 articles were analyzed. The generation of the allocation sequence was adequate in 58.3%
of the reports; treatment allocation was concealed in 34.8%. Adequate blinding was reported in one-fifth of
the reports. An intention-to-treat analysis was described in 79.5%. The main outcome was a surrogate
angiographic endpoint in 47.0%. The volume of interventions per center was described in two reports.
Operator expertise was described in five (3.8%) reports. The quality of reporting was better in journals with
high impact factors and in journals endorsing the CONSORT statement.
CONCLUSIONS: The current reporting of results of RCTs testing stents needs to be improved to allow
readers to appraise the risk of bias and the applicability of the results.
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BACKGROUND
In the past decade, stenting has become a routine treatment for many patients with coronary
artery disease [1]]. Stent design has evolved through various iterations, with the most important advance
being the development of drug-eluting stents (DESs). These advances were serially evaluated in
randomized clinical trials, often using restenosis as an endpoint.
RCTs are widely accepted as the gold standard for the evaluation of new treatments [2]. The design,
conduct, analysis, and reporting of RCTs should follow specific guidelines in order to provide valid results
and avoid common pitfalls [3]. However, RCTs assessing stents face specific issues related to difficulties
in blinding, the complexity of the intervention, the influence of healthcare providers, and centers’ volume of
care on treatment effect [4-8]. For example, there are important variations and evolutions in the
techniques used for stenting, such as balloon inflation pressure and use of intravascular ultrasound
guidance, as well as in the type, dosing, and duration of the pharmacological adjuvant therapy [9]. In
observational studies, the magnitude of differences in outcomes related to these factors vastly exceeds
those related to use of new drugs or devices [7]. The reporting of these data is therefore critical for an
accurate appraisal of the risk of bias and of the applicability of the results of RCTs [10, 11].
In the present study, we systematically appraised the reporting of internal and external validity data in
published reports of RCTs assessing stents for percutaneous coronary interventions (PCIs).
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METHODS
Search strategy and study selection. We identified all reports of RCTs published between January 1,
2003, and September 30, 2008, that assessed stents. We searched MEDLINE using the PubMed
interface and the Cochrane Central Register of Controlled Trials (issue 1, 2005) by using the terms
implantable device OR stents [Mesh Terms] and cardiovascular disease [Mesh Terms] with a limitation to
clinical trials published in English.
One author assessed the retrieved articles and screened the titles and abstracts to identify relevant
studies. We included articles only if the study was identified as an RCT, was published as a full-text
article, and assessed stents for PCI. We excluded case series, uncontrolled studies, articles published as
abstracts only, editorials, news, correspondence sections, articles not including a complete description of
the methods, and trials assessing other implantable devices (e.g., pacemaker, defibrillator, or cardiac
valve) or stents in other vascular diseases. Reports of RCTs assessing technical interventions or surgical
procedures where the use of stents was not systematically required were also excluded. We screened
articles for duplicate publication (i.e., the same trial published with results from different lengths of follow-
up), and selected only the original articles.
Data extraction. From a review of the relevant literature and according to the CONSORT Statement
guidelines [3], we generated a standardized data collection form that was iterated among the research
team [5]. Before data extraction, as a calibration exercise, two members of the team (M.E., I.B.)
independently evaluated a separate set of 20 reports. A meeting followed in which the ratings were
reviewed and disagreements were resolved by consensus. One reviewer (M.E.) independently completed
all the data extractions. A second member of the team (I.B.) reviewed a random sample of 25 articles as a
quality assurance exercise. The data abstraction form is available upon request [see additional file 1].
Trial characteristics. We collected data on trial characteristics: year of publication, funding source
(public, manufacturer, or both), number of centers, setting (primary, secondary, or academic), sample
size, primary and secondary outcomes, experimental treatment (DES, bare-metal stent [BMS], polymer-
coated stent, specific procedure of implantation such as intravascular ultrasound-guided stenting that
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could involve various categories of stents), and control treatment (stent, specific procedure of
implantation, surgery, angioplasty, pharmacological treatment, or other). We also checked whether
statistical analyses were reported to have been performed by a center independent of the sponsor.
Study quality. The quality of reporting was assessed using CLEAR NPT – a checklist specifically
developed to evaluate the quality of RCTs assessing nonpharmacological treatments [12]. These items
focus on the reporting of the generation of allocation sequence; allocation concealment; details of the
intervention administered in each group; operator volume; blinding of patients, care providers and
outcome assessors; follow-up schedule; and intention to treat analysis. We also assessed whether the
groups were described as being similar at baseline regarding the main prognostic factors and whether
eligibility criteria were specified.
Outcomes. We checked whether the primary outcomes concerned a clinical event such as death, cardiac
death, myocardial infarction, stroke, and revascularization, or an angiographic surrogate outcome such as
coronary restenosis or late lumen loss.
Description of the intervention. We recorded reporting of details on the intended interventions and on
the procedural characteristics as they were actually implemented. We checked which component of the
intervention was described: anesthesia management, access site, equipment (e.g., wire, guide), stent
(e.g., device description, manufacturer), the procedure (e.g., use of predilatation balloon, number of
inflations, duration of inflations, number of implanted stents, number of attempted lesions successfully
treated, procedure duration), co-interventions and adjuvant pharmacotherapy (either mandated or left to
operator’s discretion).
The reporting of a method to standardize the procedure, a definition of successful procedure, and the
reporting of the rate of successful procedures was also recorded.
Description of care providers and centers. Data were recorded on the number of centers involved,
center volume for the experimental treatment and for similar interventions, and the equipment in each
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center. We checked whether the list of centers was provided along with the number of patients treated in
each. Additionally, the following data on the care provider were retrieved: reporting of selection criteria for
operator (i.e., operators reported as experienced, trained, or as having performed a specific number of
interventions, operators’ years of practice or rates of complications); the number of operators performing
the experimental intervention; and the number of patients treated by each operator.
Finally, we checked whether the clustering effect of patients by healthcare providers and centers was
taken into account. In fact, in trials assessing nonpharmacological treatments, observations for
participants treated by the same healthcare provider are not independent but may be clustered in
individually randomized trials. This type of clustering is likely to affect the effect estimates because it will
inflate the standard error and reduce the effective sample size, thus reducing the power of the trial [13,
14]. This type of clustering should consequently be taken into account in sample size calculation and
statistical analyses.
Statistical analysis. We reported descriptive statistics for quantitative variables: mean, standard
deviation (SD), median (Q1 to Q3), and minimum and maximum values. Categorical variables are
described with frequencies and percentages. We compared the quality of reporting (i.e., number of items
of CLEAR NPT adequately reported) and the sample size according to the category of stent used (active
stent [drug eluting or polymer coated] versus BMS), the journal's impact factor (<3 versus ≥3), and
whether the report followed the CONSORT statement (reporting guidelines comprising a checklist and
flow diagram to help improve the quality of reports of RCTs) in the framework of linear models with mixed
effects. For instance, in a first model, the percentage of items with external validity was the dependant
variable, the category of stents was the fixed effect on which F test was performed and journal was
entered in the model as a random effect. So, mean comparisons of percentage of items with external
validity between active and BMS stents were adjusted for the clustering effect of articles by journals as
been as recommended (15).
All analyses were performed using the SAS system for Windows, release 9.1 (SAS Institute, Cary, NC).
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RESULTS
Selected articles. We screened the titles and abstracts of 867 potentially eligible reports; we examined
the full text of 255 articles and identified 132 studies that met our inclusion criteria [See additional file 2].
The trial characteristics are reported in Table 1. Twenty (15.2%) articles were published in a general
medical journal. The median sample size was 388.6 (Q1 to Q3 109.5 to 496.5) patients. The source of
funding was totally or partially private in 56 (42.4%) reports and was not reported in 57 (43.2%). The
statistical analyses were managed by independent centers in 26 (20.0%) reports.
Reporting on center and care provider. Over half (47.7%, n = 63) of the trials were multicenter (Table
2). The median number of centers was 15.4 (Q1 to Q3 1 to 22). The number of participating centers was
not reported or was unclear in 45 (34.1%) reports; the setting was described in 19 reports. The authors
provided a list of participating centers in 45 (34.1%) reports. The volume of interventions performed by
each center was described in only 2 (1.5%) reports.
Selection criteria for care providers were reported in five (3.8%) reports. These criteria were related to the
participation of “experienced” care providers, with no details on the definition of “experienced”. The
number of care providers performing the intervention or the number of patients treated by each care
provider was never reported. The clustering effect of participants by centers or by healthcare providers
was never taken into account.
Trial intervention. At least some details of the intended and actual interventions for the experimental
group were available in 121 (91.7%) and 98 (74.2%) reports, respectively (Table 2). Anesthesia
management was described in 1 (0.9%) report, arterial access site in 21 (15.9%) reports, and data related
to the equipment used in 28 (21.2%) reports. Limited data related to the procedural characteristics were
described in 98 (74.2%) reports. These data pertained mainly to the number of stents implanted and to
details regarding the inflation balloon. In 49 (37.1%) reports, no information was provided on the stent
manufacturer. The use of specific methods to standardize the procedure was never reported. A definition
of a successful intervention was provided in 51 (38.9%) reports. The rate of successful interventions was
reported in 63 (48.5%) reports. Co-interventions were described in 124 (93.9%) reports.
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Outcomes. The primary outcome relied on surrogate angiographic evaluation in almost half of the reports
(Table 3). In 18 (13.6%) reports, angiography was a component of a composite outcome and in 19
(14.4%) it was a secondary outcome. Coronary angiograms were evaluated in 99 reports and were
reported as standardized in 41.2% (40 of 99). Assessment of angiographic results was reported as
centralized in 68.7% (68 of 99) of reports and blinded in 56.6% (56 of 99).
Trial quality. Trial quality according to the CLEAR-NPT checklist is described in Table 4. For 8 out of 12
quality indexes in the checklist, the overwhelming majority of reports failed to provide appropriate
information. The generation of allocation sequence was adequate in 31 (38.8%) reports; treatment
allocation was concealed in 21 (26.3%). Patients, care providers, and outcome assessors were
adequately blinded in approximately one-fifth of the reports. An intention to treat analysis was described in
56 (70.0%) reports. Patient eligibility criteria were specified in all reports.
Factors associated with good reporting. The quality, measured by the median [Q1 to Q3] number of
items on the CLEAR NPT checklist that were adequately reported, was higher for trials published in
journals with a high impact factor versus those in a lower impact factor journal (4.0 [3.0 to 7.0] versus 3.0
[1.0 to 5.0]; p = 0.007) and in journals endorsing the CONSORT statement versus those not (7.0 [4.0 to
8.0] versus 4.0 [2.0 to 6.0]; p = 0.002), but was statistically different for active stent vs BMS (p < 0.0001).
The mean (SD) sample size was higher in journals with a high impact factor (469.2 [427.7] vs 251.8
[328.1]; p = 0.004) and when published in journals endorsing the CONSORT statement 750.6 [538.9] vs
335.1 [355.6]; p = 0.002), but was not statistically different for active stent vs BMS.
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DISCUSSION
This study evaluated the reporting of the results of RCTs assessing stents for PCIs published between
January 2003 and September 2008. Several studies have assessed the methodological quality of a broad
range of reports of randomized trials in several areas of health care [15-17]. Concerns have been raised
regarding the quality of trials assessing DESs [18]]. However, to the best of our knowledge, no study has
systematically assessed the quality of reporting of trials performed in this field.
Although some important data related to the description of the intervention intended and actually
administered, and co-interventions provided, were adequately reported, our results highlight poor reporting
of data related to the internal validity (i.e., unbiased estimates of treatment effect) and external validity
(i.e., applicability of the results) of the trials.
The assessment of internal validity highlights important pitfalls: treatment allocation was
concealed in only 34.8% of the reports; blinding of outcome assessors was reported in approximately one-
third of the reports; and intention-to-treat analysis was reported in 79.5% of the studies. Lack of reporting
of these data is associated with an increasing risk of bias, in the form of exaggerated and possibility
spurious estimates of treatment effects [19].
The choice of the primary outcome in these trials also raises some concern. In about half of the
reports, the main outcomes relied on angiographic evaluation such as coronary restenosis or late lumen
loss. These outcomes are surrogates of clinical events and their relevance may be questionable. Marked
increases in late lumen loss (>fourfold difference) are not necessarily associated with substantial
differences in major cardiac events, and thus the validity of these surrogate endpoints is questioned [18,
20]. Further, clinicians may extrapolate these results and consider the results of the trial equivalent to
clinically relevant efficacy.
In about 20% of the reports, the main outcome was a composite associating major adverse
cardiac events and revascularization. Clinical trials often use composite endpoints to reduce sample size
requirements. However, such measures may prove challenging for the interpretation of results, particularly
if the component endpoints are of widely differing importance to patients and the magnitude of effect
differs markedly across components [21-23].
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Both European Society of Cardiology [24] and American College of Cardiology/American Heart
Association/Society for Cardiovascular Angiography and Interventions [24] guidelines indicate that elective
PCIs should be performed by operators with acceptable annual volume at high-volume centers with on-
site cardiac surgery facilities [25]. In fact, there is abundant evidence that hospitals with a larger volume of
activity tend to have better outcomes and that care providers’ volume of work is also a determinant for
outcomes following revascularization [4, 25-29]. The organization of the hospital (e.g., on-site cardiologist,
activation of the catheterization laboratory by emergency physician or prehospital personnel) also impacts
outcomes [30]. This is even more marked in the context of acute coronary syndromes [7, 31]. Surprisingly,
data related to the number and expertise of the centers and operators involved in the trial were lacking,
and the potential impact of the volume was never adequately reported or taken into account in the
planning (stratification) or the analyses. Consequently, readers are unable to appraise the reports
adequately. In fact, an intervention might be found to be safe and effective in an RCT performed in high-
volume centers by high-volume operators, but it could not be assumed that these results put into practice
in low-volume centers would be identical. Unequal expertise of healthcare providers in each arm could
also bias treatment-effect estimates [32]. Likewise, procedure characteristics (inflation number, duration or
maximal pressure) and details on the surrounding management, such as data on equipment, access site,
anaesthesia management or adjuvant therapy, were frequently lacking.
Finally, in trials assessing stents, operators are integral parts of the intervention, and observations
on participants treated by the same operator may be somewhat similar or clustered [13]. This clustering
will inflate standard error and reduce trial power. Furthermore, in these settings, the assumption of
independence of data is violated, which means that standard statistical analyses are invalid and may give
misleading conclusions. However, this issue was never addressed in the statistical analyses or the sample
size calculations [14]].
Study limitations. Our search strategy and selection criteria for the reports assessed might not be
comprehensive. In fact, many trials evaluating PCIs also use stents, and these were not included since
stents were not the experimental therapy. However, our aim was to focus only on trials specifically
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assessing stents and our panel is representative of the published trials. Our analysis is based on reports
of RCTs rather than on the trials themselves. Clearly, failure to report is not equivalent to failure to actually
carry out the procedure or to implement adequate methods [20]. Consequently, poor or insufficient
reporting is not necessarily equivalent to low quality trials. However, the published report is the only
document available for readers to appraise the quality of trials, particularly in meta-analyses and
systematic reviews. Empirical evidence of bias also relies mainly on the reporting of trials [19, 33].
Conclusions. This study highlights the inadequate reporting of contemporary trials involving stents. Such
inadequate reporting is particularly problematic, as the technical advances tested are often rapidly
implemented in clinical practice without the possibility for an adequate critical assessment of the methods
used to test them.
It is desirable to increase the awareness of interventional cardiology trialists regarding checklists
and guidelines for reporting trial quality such as the CONSORT Statements. With access to electronic
reporting, detailed reporting of methods and quality assurance is easy to implement, and would
substantially increase the quality of reporting. This would be valuable to interventional cardiologists and to
the broader cardiology community for proper interpretation of the evidence regarding the use of stents in
PCI.
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Table 1. Reports’ Characteristics
n (%)
n = 132
Journal
General medical journal 20 (15.2)
Circulation
American Heart Journal
Catheter and Cardiovascular Intervention
Journal of the American College of Cardiology
American Journal of Cardiology
Other
15 (11.4)
14 (10.6)
18 (13.6)
17 (12.9)
15 (11.4)
33 (25.0)
Funding
Public funding
Manufacturer funding
Both public and manufacturer funding
No funding
Not reported
16 (12.1)
49(37.1)
7 (5.3)
3 (2.3)
57 (43.2)
Interventions
BMS 41 (31.1)
Polymer-coated stent 19 (14.4)
DES 64 (48.5)
Strategy of stent implantation 8 (6.1)
Comparisons (experimental intervention vs control arm)
DES vs BMS 35 (26.5)
DES vs another DES 19 (14.4)
DES vs same DES but with a different dosage 5 (3.8)
DES vs balloon angioplasty 6 (4.5)
DES vs polymer-coated stent 3 (2.3)
DES vs surgery 1 (0.8)
Polymer-coated stent vs BMS 13 (9.8)
Polymer-coated stent vs angioplasty 3 (2.3)
BMS vs another BMS 13 (9.8)
BMS vs angioplasty 10 (7.6)
BMS vs surgery 9 (6.8)
BMS vs a strategy of stent implantation 6 (6.8)
Strategy of stent implantation vs another strategy of stent implantation 4 (3.0)
Strategy of stent implantation vs angioplasty 5 (3.8)
BMS = bare-metal stent
DES = drug-eluting stent
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Table 2. Reporting of the Different Components of the Intervention Intended or Actually Administered
Reporting of n = 132 (%)
Intervention as intended 121 (91.7)
Intervention as actually administered 98 (74.2)
Component of the intervention described
Anesthesia management 1 (0.9)
Access site (i.e. transfemoral access site) 21 (15.9)
Data on equipment (i.e., guide catheters, wires) 28 (21.2)
Data on stent 99 (75.0)
Left to operator’s discretion 5 (3.8)
Description of the device (i.e., length, component) 74 (56.1)
Manufacturer 83 (62.9)
Procedural characteristics 98 (74.2)
Number of stents implanted 73 (55.3)
Use of dilatation balloon 59 (44.7)
Number of inflations 9 (6.8)
Duration of inflation 12(9.1)
Number attempted and successfully treated 12 (9.1)
Procedure duration 8 (6.1)
Co-interventions 124 (93.9)
Setting
Secondary setting 1 (0.8)
Tertiary or academic setting 18 (13.6)
Not reported 113 (85.6)
Center
Single 24 (18.2)
Multicentre 63 (47.7)
Not reported or unclear 45 (34.1)
Centers
Stratification on centers 10 (7.6)
Number of centers (median, Q1 to Q3) 15.4 (1-22)
List of participating centers 45 (34.1)
Center volume reported 2 (1.5)
Source of equipment reported 1 (0.8)
Specific equipment required 0
Operators
Selection criteria for operators 5 (3.8)
Number of operators (median, Q1 to Q3) 5.5 (5-6)
Number of patients treated by each operator 0
Clustering effect taken into account 0
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Table 3. Primary Outcomes Reported In Randomized Controlled Trials Assessing Stents
Primary Outcome
N (%)
N = 132
Angiographic evaluation (e.g., coronary restenosis) 62 (47.0)
Major cardiac events and repeat revascularization 25 (18.9)
Major cardiac events, repeat revascularization and angiographic evaluation 8 (6.1)
Repeat revascularization 7 (5.3)
Major cardiac events 8 (6.1)
Other 22 (16.7)
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Table 4. Assessment of the Quality of Selected Randomized Controlled Trials Using the CLEAR NPT
Checklist
Yes
n (%)
No
n (%)
Unclear
n (%)
Adequate generation of allocation of sequence 77 (58.3) 0 55(41.7)
Concealment of treatment allocation 46 (34.8) 0 86 (65.2)
Details of intervention used in each group available 125 (94.7) 0 7 (5.3)
Care providers’ experience or skill in each arm appropriate 3 (2.3) 0 129 (97.7)
Participants adequately blinded 23 (17.4) 63 (47.7) 46 (34.9)
Care providers adequately blinded 16 (12.1) 74 (56.1) 42 (31.8)
If patients and/or care providers were not adequately blinded:
All other treatments and care were the same in each group 97 (73.5) 5 (3.8) 9 (6.8)
Withdrawals and lost to follow-up were the same in each
group
46 (34.8) 6 (4.5) 61 (46.2)
Outcome assessors adequately blinded to assess the primary
outcomes
39 (29.5) 44 (33.3) 49 (37.1)
If outcome assessors were not adequately blinded:
Specific methods were used to avoid ascertainment bias 2 (1.5) 13 (9.8) 76 (57.6)
Follow-up schedule was the same in each group 105 (79.5) 2 (1.5) 23 (17.4)
Main outcomes analyzed according to the intention-to-treat
principle
105 (79.5) 17 (12.9) 10 (7.6)
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